Research Article

The Chinese Herbal Medicine Formula Sheng-Fei-Yu-Chuan-Tang Suppresses Th2 Responses and Increases IFN-γ in Dermatophagoides pteronyssinus Induced Chronic Asthmatic Mice

Chia-Hung Lin,1 Ching-Hua Yeh,2 Li-Jen Lin,3 Jen-Shu Wang,4 Shulhn-Der Wang,5 and Shung-Te Kao1,6,7

1 Graduate Institute of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
2 Graduate Institute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan 71101, Taiwan
3 School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
4 Institute of Medical Science, Tzu Chi University, Hualien 97004, Taiwan
5 School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
6 Department of Chinese Medicine, China Medical University Hospital, Taichung 40402, Taiwan
7 School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan

Correspondence should be addressed to Shulhn-Der Wang; wsd917@ms42.hinet.net and Shung-Te Kao; stkao@mail.cmu.edu.tw

Received 31 October 2012; Accepted 18 February 2013

Academic Editor: Taixiang Wu

Copyright © 2013 Chia-Hung Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sheng-Fei-Yu-Chuan-Tang (SFYCT), a traditional Chinese medicine formula consisting of 13 medicinal plants, has been used in the treatment of asthma. This study demonstrated the immunoregulatory effect of SFYCT on chronic allergic asthma using the Dermatophagoides pteronyssinus- (Der p-) challenged chronic asthmatic murine model. SFYCT decreased the airway hyperresponsiveness (AHR), pulmonary inflammatory cell infiltration, and airway remodeling in Der p mice. SFYCT treatment decreased Derp-induced total IgE and Der-p-specific IgG1 but not IgG2a/2b Ab titer in serum of Der p mice. SFYCT also decreased Th2 cytokines, IL-4, IL-5, and IL-13, but increased IFN-γ and IL-12 in the BALF of Der p mice. TGF-β1 and collagen production in the lung of mice were decreased by SFYCT. The mRNA expression of chemokine including Eotaxin, RANTES, and MCP-1 in the lung of Der p mice was decreased by SFYCT. In conclusion, the suppressed Der-p-induced airway inflammation, remodeling, and hyperresponsiveness in chronic asthma murine model are related to SFYCT inhibits Th2 responses, decreases chemokine expression and promotes IFN-γ and IL-12 production. SFYCT could show Der-p-induced Th2 responses to Th1 responses by increasing IFN-γ which is merit for clinical application on asthma patients.

1. Introduction

Allergic asthma, an acute-on-chronic inflammatory disease, is a worldwide public health problem because of the rapidly increasing prevalence [1]. The characteristics of allergic asthma induced by inhaled allergens or nonspecific stimuli include airway eosinophilia, goblet cell hyperplasia with mucus hypersecretion, collagen deposition, and smooth muscle cell hypertrophy in lung, subepithelial thickening, and hyperresponsiveness in airway [2]. T-cell subsets, T helper 1 (Th1) and T helper 2 (Th2), response to allergens and regulate immune reactions during asthma. Asthma is considered a Th2-cell-driven inflammatory disease [3]; thus, drugs that can suppress Th2 cytokine production would prove useful as allergen immunotherapy agents [4]. However, antiasthmatic medicines, such as corticosteroids or β-agonists, help chronic asthmatic patients to inhibit asthmatic symptoms but not to cure the disease [5]. These agents cause serious side effect, overall immune suppression which results in increased susceptibility to infections, particularly in children [6, 7]. Thus, more and more asthmatic patients starting to use
complementary and alternative medicine [8]. Traditional Chinese medicines (TCMs) have been used in treating asthma for centuries in Asia [9]. Some herbal formulas, herbal derivatives, and TCMs have provided scientific evidence supporting the use of treating allergic asthma by immune-regulatory effects [10–13]. These findings suggest a great potential in the development of herbal interventions to treat allergic asthma.

Sheng-Fei-Yu-Chuan-Tang (SFYCT), a formula on the basis of an empirical traditional Chinese medicine prescription composite of 13 medicinal plants (Table 1), has been used to treat bronchial asthma for decades in the Veterans General Hospital, Taichung, Taiwan. In the present study, the therapeutic effect on asthmatic syndrome of SFYCT was investigated in a Dermatogoides-pteronyssinus- (Der-p-) induced allergic asthma murine model [14]. Repeatedly exposing BALB/c mice to Der p via intratracheal (i.t.) exposure induces lymphocyte proliferation, Th2 cytokine release, airway inflammation, and remodeling [12]. Th2 cytokines, IL-4, IL-13, and IL-5 produced by activated CD4+ T cells, play a central role in the pathogenesis of allergic asthma [15]. IFNy is a key cytokine in bridging the innate and the adaptive arms of the immune system and helps the development of a Th1-type response [16]. Because asthma is associated with dysregulated Th2 responses, enhanced Th1 responses may suppress the development of allergic airway inflammation. Therefore, strategies that enhance Th1 responses or increase IFNy production have been proposed as therapies for ameliorating allergic airway inflammation [17, 18]. In the present study, we investigated the immunoregulatory effect of SFYCT on Der-p-induced chronic asthmatic murine model. Most treatments including corticosteroids and TCMs reduce AHR and airway inflammation by inhibiting Th1 responses (IFN-γ/IgG2a) as well as Th2 (IL-4, IL-5, and IL-13/IgE) responses [4, 8, 9, 11–13, 19]. However, SFYCT suppressed Th2 cytokines but elevated IFN-γ and IL-12 production. To our knowledge, this is the first TCM formula, SFYCT, documented supresses pulmonary allergic reactions through skewing Der p-induced Th2 responses to Th1 responses by increasing IFN-γ and IL-12. The present study demonstrates that SFYCT may offer some clinical advantages over corticosteroids because it is less likely to increase the patient’s susceptibility to infection.

2. Materials and Methods

2.1. Mice and Reagents. Specific pathogen-free, male, 6 wk old BALB/c mice from the National Laboratory Animal Center, ROC, were housed in a microisolator cage and fed sterile food and water ad libitum. All experimental animal care and treatment followed the guidelines setup by the Institutional Animal Care and Use Committee of the China Medical University. Lyophilized house dust mites (Dermatophagoides pteronyssinus (Der p)) were purchased from Allergon (Engelholm, Sweden). Crude mite preparation was extracted with ether. After dialysis with deionized water, the mite extract was lyophilized and stored at −70°C until use. LPS concentration of the Der p preparations was 1.96 EU/mg of Der p (Limulus amebocyte lysate test; E-Toxate; Sigma-Aldrich).

2.2. SFYCT Preparation. SFYCT (batch number 98041021) was supplied by Koda Pharmaceuticas Ltd. (Taoyuan, Taiwan). The preparation was a mixture of 13 Chinese herbal medicines shown in Table 1. In brief, these were extracted with 1 L of boiled water twice for 1 hr. Poaching liquid was mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two times. The dregs of the decoction were removed and mixed two ti

### Table 1: The ratio of the components in SFYCT.

| Components | Amount (g) |
|------------|------------|
| Ginseng Radix (root of *Panax ginseng* C. A. Meyer) | 4 |
| Atractylodis Ovatae Rhizoma (root and rhizome of *Atractylodes macrocephala Koide*) | 4 |
| Citri Reticulatae Pericarpium (skin of fruit of *Citrus reticulate Blanco*) | 4 |
| Ephedrae Herba (stem of *Ephedra sinica* Stapf) | 1.2 |
| Mori Ramulus (branch of *Morus alba L.*) | 4 |
| Radix Bupleuri (root of *Bupleurum chinense DC*) | 4 |
| Cinnamomi Ramulus (root of *Cinnamomum cassia* BL) | 4 |
| Scutellariae Radix (root of *Scutellaria bicalensis* George) | 4 |
| Schizonepetae Herba (stem of *Schizonepeta tenuifolia* Briq) | 6 |
| Sileris Radix (root of *Siler divaricatum* Bent th et Hook L.) | 6 |
| Glycyrrhizae Radix (root of *Glycyrrhiza uralensis* Fisch) | 4 |
| Zingiberis Recens Rhizoma (root and rhizome of *Zingiber officinale* Rosc.) | 2 |
| Zizyphi Sativae Fructus (fruit of *Zizyphus jujube* Mill. Var. inermis Rehd.) | 6 |
| Total amounts | 53.2 |

In parallel experiments, normal mice were gavaged with SFYCT (1 g/kg) 30 min before Der p challenge.
distilled water and i.t. administered PBS as control group. Mice were killed by i.p. injection of xylazine (200 μg/mice) and ketamine (2 mg/mice) 3 days after the last challenge. Bronchoalveolar lavage fluid (BALF) was performed (two washes of 1 mL of ice-cold endotoxin-free PBS) according to a previously described procedure [11]. Serum and BALF were collected and stored at −80°C for further analysis. Differential counts were performed on cytospin preparations (1 × 10^5 cells/100 μL of BALF) stained with Liu’s stain reagents (Biotech, Taiwan) in a blind manner after leucocyte counting.

2.4. Measurement of Airway Hyperresponsiveness. The methacholine-induced pause value was used in live mice as a marker of airway responsiveness (AHR) to bronchoconstrictors. AHR was measured in mice using a single-chamber, whole-body plethysmograph (Buxco Electronics, Inc., Troy, NY, USA) according to the manufacturer’s protocol. The enhanced pause (Penh) variable was used to estimate airway resistance. Mice were serially exposed to increasing doses of nebulized methacholine (0, 3.125, 6.25, 12.5, 25, and 50 mg/mL) (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 3 minutes, respectively, and Penh values were measured for 3 minutes following the end nebulization of methacholine.

2.5. Histology Examination. Paraffin-embedded lung was cut into 5 μm sections and stained with H&E or periodic-acid-Schiff (PAS) stain. Light microscopy was used for histologic assessment. The degree of inflammatory changes was evaluated with a semiquantitative scale of 0–5 for inflammatory cell infiltration, perivascular spaces, and peribronchial spaces. The scale was graded as follows: 0 (none), 1 (minimal, <1%), 2 (slight, 1–25%), 3 (moderate, 26–50%), 4 (moderate/severe, 51–75%), and 5 (severe/high, 76–100%) [20].

2.6. Collagen Analysis. The lung tissue (100 mg) of each mice was homogenized mechanically in 2 mL HBSS. The collagen contents of the lung homogenates were analyzed using Sircol collagen assay kit (Biocolor, Belfast, UK).

2.7. Flow Cytometric Analysis. Monoclonal antibodies including PE and/or FITC-conjugated anti-mouse CD4, FITC-conjugated anti-mouse CD8, PerCP-conjugated anti-mouse CD3, and FITC-conjugated anti-mouse CD25 (BD Pharmingen) were used for cell fluorescence staining. BALF cells (1 × 10^6) were stained with mAb for 30 min on ice. After washing, stained cells were quantified by FACScan (Becton-Dickinson Immunocytometry system, San Jose, CA, USA).

2.8. Measurement of Der-p-Specific IgG1, IgG2a/2b, and IgE. An IgE-specific ELISA was used to measure the total IgE Ab levels in serum using matching mAb pairs (BD Pharmingen) according to the manufacturer’s instructions. A450 readings of the samples were converted to ng/mL using a standard curve generated with double dilutions of mouse IgE isotype standard (BD Pharmingen). For Der-p-specific Abs, serum samples were added in duplicate onto ELISA plates coated with Der p (2 g/mL in 0.1 M NaHCO₃, pH 8.3). After incubation overnight at 4°C, the plates were washed and incubated with biotinylated rat anti-mouse IgG1 or IgG2a/2b monoclonal Ab (2 g/mL; BD PharMingen) for 1 h, followed by washings with PBS and the addition of streptavidin-HRP conjugate (1:1000 dilution, BD Pharmingen). The plates were washed and developed with a tetramethylbenzidine microwell peroxidase substrate system (Kirkegaard & Perry Laboratories, Gaithersburg, MD) and read at OD 450.

2.8.1. Measurement of Cytokine Levels Concentration. Cytokine concentration was measured by a sandwich ELISA technique. Mouse IL-4, IL-5 ELISA Ready-SET-Go (eBioscience, San Diego, CA), IL-12, IL-13, INF-γ, and TGF-β ELISA DuoSet (R&D System, Abingdon, UK) were used to detect cytokine concentrations according to the manufacturer's protocol.

2.9. Reverse Transcription-Polymerase Chain Reaction. Reverse transcription-polymerase chain reaction (RT-PCR) was performed to determine the Eotaxin, RANTES, monocyte chemotactic protein (MCP)-1 or β-actin mRNA expression. Total RNA of lung was extracted using Trizol solution (Life Technologies) and subjected to reverse transcription with StrataScript H-reverse transcriptase (Strata-gene, La Jolla, CA, USA) to generate cDNA. Gene-specific primer pairs (sense and antisense, resp.) used are as follows: RANTES, F5’-AGAAGTTGGTTCAAGAATACAT-3’ and R5’-GGGCTGAGTGTTGAGTAG-3’; Eotaxin, F5’-ACCTGTTACATTAGAATAATGGTT-3’ and R5’-AGGCTGCCCTGATCTAC-3’; MCP-1, F5’-ACCTGCTGCTACTCATTACATTTAGAATAATGGTT-3’ and R5’-AGGCTGCCCTGATCTAC-3’; β-actin, F5’-GCTGGAAGGTGGGAGTAG-3’ and R5’-GGGCTGAGTGTTGAGTAG-3’.

PCR products were electrophoresed on 1.5% agarose gels and stained with ethidium bromide. β-Actin amplification was used as an internal control. The relative quantity of PCR products is expressed as fold increase relative to β-actin.

2.10. Statistical Analysis. Data are presented as means ± SE. Differences between mean values were estimated using a Student’s t-test. A P value < 0.05 was considered significant. For comparisons of data that were not normally distributed, a Mann-Whitney U test was performed.

3. Results

3.1. Effects of SFYCT on Airway Inflammation and Hyperresponsiveness in Der p Mice. Most allergic asthmatic patients are sensitized by house dust mite allergens, such as Der p [14]. Thus, repetitive Der p challenge protocol described in Section 2 was used to induce chronic airway inflammation in mice. Repeatedly exposing BALB/c mice to Der p via intratracheal (i.t.) exposure induces lymphocyte proliferation, Th2 cytokine release, airway inflammation, and remodeling [12]. In the present study, 3 days after the last challenge, the numbers and percentages of macrophages, neutrophils, eosinophils, and lymphocytes in the BALF of nontreated Der p mice significantly higher than those of control mice (Table 1). AHR, determined using Penh values, in Der p mice
3.2. Effects of SFYCT on Inflammatory Cell Number and Cellular Distributions in BALF of Der p Mice. The total and various cell counts in BALF from normal mice and Der p mice with or without SFYCT treatment were analyzed (Table 2). In the BALF of normal mice, there were few macrophages, lymphocytes, or neutrophils but no eosinophil was detected. In Der p mice, all kinds of inflammatory cell numbers in BALF were markedly increased but SFYCT treatment significantly decreased them.

The T-cell subset distribution in the BALF of mice was determined by flow cytometry. The percentages of CD3+ /CD4+, CD3+ /CD8+, and CD4+ /CD25+ lymphocytes in Der p mice were significantly higher than in normal mice. SFYCT treatment decreased the CD3+ /CD4+ and CD4+ /CD25+ lymphocyte percentage but barely affected CD3+ /CD8+ lymphocyte in BALF of Der p mice (see Figure 3).

3.3. Effects of SFYCT on Cytokine in Serum and BALF of Der p Mice. To determine the possible effect of SFYCT on T-cell responses, the levels of T-cell cytokine concentration and Ab titers in the BALF or serum of Der p mice were analyzed by ELISA. SFYCT treatment significantly decreased the levels of Der p-induced cytokine, IL-5, IL-13, IL-17 and TGF-β, but enhanced IFNγ as well as IL-12 secretion in BALF of Der p mice (Figure 4). The elevated serum levels of IL-4 and IL-5 in Der p mice were reduced by SFYCT (Figure 5). Furthermore, the serum levels of total IgE and Der-p-specific IgE in mice were increased after repeated Der p challenge and SFYCT treatment reversed the phenomenon. The levels of IgG1 normally associated with a Th2 immune response while IgG2a/2b associated with a Th1 immune response [5, 21]. The serum titers of IgG1 and IgG2a/2b Abs were elevated in Der p mice suggesting a mixed Th1/Th2 response. SFYCT treatment decreased the IgG1 but not IgG2a/2b Ab titer in serum of Der p mice (Figure 5).

3.4. Effect of SFYCT on Chemokine Expression in the Lung of Der p Mice. The mRNA expression of chemokines including Eotaxin, RANTES, and MCP-1 in the lung of mice was analyzed by RT-PCR. The mRNA expressions of these chemokines were higher in Der p mice than those in normal mice. SFYCT treatment significantly inhibits the increased Eotaxin, RANTES, and MCP-1 mRNA in the lung of Der p mice (see Figure 6).

4. Discussion

TCMs have been reported with therapeutic effects on allergic asthma [19, 22]. SFYCT, a formula designed following the traditional Chinese medicine theories and clinical experience, has been used to treat asthmatic patients in Taiwan for decades. Unlike the side effect from using corticosteroids, SFYCT relieves asthmatic syndrome without total immune suppression. In present study, the immunoregulatory effects and possible mechanism of SFYCT were investigated in Der p-induced chronic allergic asthma murine model. SFYCT treatment suppressed airway inflammation, AHR, and Th1 response but increased IFNγ and IL-12 production in asthmatic mice.

SFYCT exhibited nonspecific anti-inflammatory property with reducing the cell number of all kinds of inflammatory cells in the BALF of Der p mice. Pathological observations also showed that SFYCT reduced inflammatory cell infiltration. Airway remodeling, including lamina thickening and airway structural changes, a central feature of asthma, is closely related to progression of AHR [21, 23]. TGF-β not only regulates cellular biological processes leading to airway remodeling [24] but also contributes to increased collagen synthesis and AHR [25]. Treatment with the antibody to TGF-β reduced the number of mucus-secreting goblet cells in a murine model of asthma [26]. Although corticosteroids
Figure 2: The effects of SFYCT on Der-p-induced airway inflammation, goblet cell hyperplasia, mucus hypersecretion, and collagen deposition in lung tissue of mice. (a) H&E stain and inflammatory score show the histopathologic change and inflammatory cell infiltration around the blood vessels of mice. (b) PAS stain shows the mucus of goblet cells in the airway of mice. Goblet cell hyperplasia and mucus plug in airway from PBS sham treated mouse and nontreated or SFYCT treated Der p mouse. (c) Collagen levels in the lung of mice were determined as described in Section 2. Values represent the means ± SE of 6 mice. *P < 0.05 compares with Naive group; #P < 0.05 compare with Der p group.

Table 2: The total cell number and cellular distributions in BALF of mice 72 h after repetitive Der p challenge.

|                  | Total cells (×10⁴/mL) | Macrophages (%) | Lymphocytes (%) | Neutrophils (%) | Eosinophils (%) |
|------------------|-----------------------|-----------------|-----------------|-----------------|----------------|
| PBS              | 16.5 ± 1.73           | 15.57 ± 1.85    | 0.61 ± 0.22     | 0.32 ± 0.22     | 0              |
| Der p            | 71.25 ± 4.43*         | (94.36 ± 11.20)| (3.68 ± 1.33)  | (1.95 ± 1.36)  | (0)            |
| SFYCT            | 40.25 ± 3.5**         | (50.39 ± 3.35*) | (3.81 ± 1.69*) | (13.16 ± 1.63*)| (4.28 ± 0.27*) |

Values represent the mean ± SE of 6 mice. *P < 0.05 compares with naive; **P < 0.05 compares with Der p.

and β2 agonists are able to improve the management of asthma, they are ineffective at inhibiting TGF-β to reverse the structural remodeling of airways, especially in patients with chronic asthma [27–29]. SFYCT treatment decreased the TGF-β production in BALF and collagen synthesis in the lung of Der p mice. Taken together, these results suggest that treatment with SFYCT can suppress AHR by decreasing airway inflammation and mucus hypersecretion associated with TGF-β secretion. The properties of SFYCT with anti-inflammation, decreasing airway remodeling, and inhibiting AHR promise this formula an effective therapeutic modality for asthma.

Immunoglobulin E (IgE), an important mediator of allergic reactions, plays a central role in airway inflammation...
and asthma-related symptoms. Anti-IgE therapies have the potential to block an early step in the allergic cascade [21]. In the serum of Der p mice, high level of Der-p-specific IgG1 Ab, is associated with a Th2 immune response [30]. By contrast, increasing IgG2a production is considered to be beneficial for asthma treatment [31]. SFYCT treatment significantly decreased Der-p-specific IgE and IgG1 but slightly increased IgG2a/2b in the serum of Der p mice. These data suggested that the benefit of SFYCT treatment might be related to inhibiting Th2 response. Furthermore, Th2 cell play an important role in orchestrating the asthmatic inflammatory response [32]. The flow cytometry analysis showed that SFYCT treatment decreased the percentage of the CD3+ /CD4+ T-cell subset in BALF but increased the CD3+ /CD8+ T-cell subset. These data suggested that SFYCT could modulate the Th-cell differentiation from Th2-cell dominant to Th1-cell dominant in the airway of chronic asthmatic mice.

IFNγ is a key cytokine in bridging the innate and the adaptive arms of the immune system and helps the development of a Th1-type response [16]. SFYCT increased the IFN-γ secretion in the BLAF of Der p mice. This immunoregulation may be more beneficial than Th1 cytokine (IFN-γ and IL-12) or Th1 adjuvant therapy, which may cause undesirable inflammation because of higher-than-normal levels of Th1 cytokines [33]. IL-12, produced by antigen-presenting cells, promotes differentiation of Th1 cells, IFN-γ production, and inhibits differentiation of Th0 cells into IL-4–secreting Th2 cells [34]. Because SFYCT induced IFN-γ and IL-12 as well as reduced IL-4 and IL-5 production in BALF, whether this effect was dependent on IL-12 should be further investigated.

Corticosteroids are the most powerful nonspecific anti-inflammatory drugs routinely used to treat asthma. However, it is also well known that corticosteroids produce overall immune suppression, which results in increased susceptibility to infections. Corticosteroid immunosuppression is due to induction of T-lymphocyte apoptosis [6]. In this study, SFYCT decreased the cell number of macrophage, neutrophil, and eosinophil but not lymphocyte in BALF of Der p mice. FASCs results also showed that SFYCT did not decrease the distribution of CD3+ /CD8+ T-cell subset. These results suggest that SFYCT is not toxic to all lymphocytes, especially Th1-related lymphocyte. These findings, together with SFYCT suppressing Th2 cytokines accompanied with increasing IFN-γ secretion, clearly demonstrate that SFYCT actions on T cells differ from corticosteroids and suggest that SFYCT might be of more benefit to asthma patients.
Th2 cytokines play a central role in the pathogenesis of asthma. IL-4 or IL-13 promotes B-cell switching to IgE production and mucus hypersecretion. IL-5 has been shown to be the primary determinant of eosinophil priming, activation, recruitment, and survival [15, 16]. Anti-IL-4 or anti-IL-13 receptor antibodies could suppress antigen-induced AHR but not eosinophilic inflammation [35, 36]. AHR is regulated by integrated IL-13, IL-4, and IL-5 signals [37]. Compared with the sham treated group, SFYCT treatment decreased three major Th2 cytokines, IL-4, IL-5, and IL-13, production in serum or BALF in Der p mice. It seems that SFYCT is offering advantage over therapeutic administration of single antibodies against IL-4, IL-5, or IL-13 or their receptors since natural allergic airway reactions are mediated by a combination of Th2 cytokines. Furthermore, IL-17 was demonstrated as indispensable to induce granulocyte influx into the lung in allergic asthma model [38, 39]. IFN-γ is indicated to limit the IL-17-producing T-cell population [40]. IL-17 is mainly
produced by macrophages in allergic inflammation related to asthma [41]. We found that IL-17 production and macrophage infiltration were attenuated while IFN-γ production was increased in SFYCT treated mice. These observations suggest that SFYCT could limit the IL-17 related immune response by increasing IFN-γ production.

After asthma attack, Eotaxin and RANTES are chemottractants for eosinophils [42] while RANTES and MCP-1 are involved in recruiting monocytes [43, 44] from system to lung. Asthma-relevant chemokines, mentioned above, have been targeted by humanized blocking mAb to their receptors or removal of chemokines via soluble receptors or small molecule receptor antagonists [44]. Here, SFYCT decreased the mRNA expression of Eotaxin, RANTES, and MCP-1 in the lung of Der p mice which may contribute to the reduction in eosinophils and monocyte recruitment in airway.

In conclusion, SFYCT suppressed Der-p-induced airway inflammation, remodeling, and hyperresponseness in
chronic asthma murine model. The effect was accompanied by inhibiting Th2 responses and decreasing chemokine expression but elevating IFN-γ and IL-12 production. This is the first study of TCM formula, SFYCT, documented that may attenuate asthma symptoms through skewing Der-p-induced Th2 responses to Th1 responses by increasing IFN-γ and IL-12. SFYCT provides more clinical advantages over corticosteroids for asthma treatments.

**Authors’ Contribution**
Shulhn-Der Wang and Shung-Te Kao equally contributed to this paper.

**Acknowledgments**
This work was supported by grants from the National Science Council, Taiwan (NSC 94-2320-B-039-005 and NSC 99-2313-B-309-001-MY3).
References

[1] H. Hammad and B. N. Lambrecht, “Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses,” Allergy, vol. 66, no. 5, pp. 579–587, 2011.

[2] Q. Hamid and M. Tulic, “Immunobiology of asthma,” Annual Review of Physiology, vol. 71, pp. 489–507, 2009.

[3] C. M. Lloyd and E. M. Hessel, “Functions of T cells in asthma: more than just TH2 cells,” Nature Reviews Immunology, vol. 10, no. 12, pp. 838–848, 2010.

[4] S. J. Levine and S. E. Wenzel, “Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes,” Annals of Internal Medicine, vol. 152, no. 4, pp. 232–237, 2010.

[5] C. H. Fanta, “Drug therapy: Asthma,” The New England Journal of Medicine, vol. 360, no. 10, pp. 1002–1004, 2009.

[6] G. Migliorati, I. Nicoletti, G. Nocentini, M. C. Pagliacci, and C. Riccardi, “Dexamethasone and interleukins modulate apoptosis of murine thymocytes and peripheral T-lymphocytes,” Pharmacological Research, vol. 30, no. 1, pp. 43–52, 1994.

[7] Z. Diamant, J. Diderik Boot, and J. Christian Virchow, “Summing up 100 years of asthma,” Respiratory Medicine, vol. 101, no. 3, pp. 378–388, 2007.

[8] C. Steurer-Stey, E. W. Russi, and J. Steurer, “Complementary and alternative medicine in asthma—do they work? A summary and appraisal of published evidence,” Swiss Medical Weekly, vol. 132, no. 25-26, pp. 338–344, 2002.

[9] X. M. Li and L. Brown, “Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy,” Journal of Allergy and Clinical Immunology, vol. 123, no. 2, pp. 297–306, 2009.

[10] Y. Y. Kung, Y. C. Chen, S. J. Hwang, T. J. Chen, and F. P. Chen, “The prescriptions frequencies and patterns of Chinese herbal medicine for allergic rhinitis in Taiwan,” Allergy, vol. 61, no. 11, pp. 1316–1318, 2006.

[11] S. T. Kao, S. T. Wang, C. K. Yu, H. Y. Lei, and J. Y. Wang, “The effect of Chinese herbal medicine, xiao-qing-long tang (XQLT), on allergen-induced bronchial inflammation in mite-sensitized mice,” Allergy, vol. 55, no. 12, pp. 1127–1133, 2000.

[12] L. J. Lin, C. C. Lin, S. D. Wang, Y. P. Chao, and S. T. Kao, “The immunomodulatory effect of You-Gui-Wan on dermatogoides-pyrogenyssinus-induced asthma,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 476060, 12 pages, 2012.

[13] I. Ziment and D. P. Tashkin, “Alternative medicine for allergy and asthma,” Journal of Allergy and Clinical Immunology, vol. 106, no. 4, pp. 603–614, 2000.

[14] W. R. Thomas, B. J. Hales, and W. A. Smith, “House dust mite allergens in asthma and allergy,” Trends in Molecular Medicine, vol. 16, no. 7, pp. 321–328, 2010.

[15] S. Romagnani, “The role of lymphocytes in allergic disease,” Journal of Allergy and Clinical Immunology, vol. 105, no. 3, pp. 399–408, 2000.

[16] M. Akdis, S. Burgler, R. Cramer et al., “Interleukins, from I to 37, and interferon-γ: Receptors, functions, and roles in diseases,” Journal of Allergy and Clinical Immunology, vol. 127, no. 3, pp. 701–721, 2011.

[17] B. Bosnjak, B. Stelzmueller, K. J. Erb, and M. M. Epstein, “Treatment of allergic asthma: modulation of TH2 cells and their responses,” Respiratory Research, vol. 12, p. 114.

[18] S. E. Kim, J. H. Kim, B. H. Min et al., “Crude extracts of Caenorhabditis elegans suppress airway inflammation in a murine model of allergic asthma,” PLoS One, vol. 7, no. 4, Article ID e35447.

[19] X. M. Li, “Treatment of asthma and food allergy with herbal interventions from traditional chinese medicine,” Mount Sinai Journal of Medicine, vol. 78, no. 5, pp. 697–716.

[20] C. C. Lee, J. W. Liao, and J. J. Kang, “Motorcycle exhaust particles induce airway inflammation and airway hyperresponsiveness in BALB/C mice,” Toxicological Sciences, vol. 79, no. 2, pp. 326–334, 2004.

[21] K. F. Rabe, W. J. Calhoun, N. Smith, and P. Jimenez, “Can anti-IgE therapy prevent airway remodeling in allergic asthma?” Allergy, vol. 66, no. 9, pp. 1142–1151, 2011.

[22] L. Bielory and K. Lupoli, “Herbal interventions in asthma and allergy,” Journal of Asthma, vol. 36, no. 1, pp. 1–65, 1999.

[23] E. Tagaya and J. Tamaoki, “Mechanisms of airway remodeling in asthma,” Allergology International, vol. 56, no. 4, pp. 331–340, 2007.

[24] R. Halwani, S. Al-Muhsen, H. Al-Jahdali, and Q. Hamid, “Role of transforming growth factor-β in airway remodeling in asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 2, pp. 127–133, 2011.

[25] I. Gomes, S. K. Mathur, B. M. Espenshade, Y. Mori, J. Varga, and S. J. Ackerman, “Eosinophil-fibroblast interactions induce fibroblast IL-1β secretion and extracellular matrix gene expression: implications in fibrogenesis,” Journal of Allergy and Clinical Immunology, vol. 116, no. 4, pp. 796–804, 2005.

[26] S. J. McMillan, G. Xanthou, and C. M. Lloyd, “Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-β antibody: Effect on the Smad signaling pathway,” Journal of Immunology, vol. 174, no. 9, pp. 5774–5780, 2005.

[27] J. Chakir, J. Shannon, S. Molet et al., “Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression,” Journal of Allergy and Clinical Immunology, vol. 111, no. 6, pp. 1293–1298, 2003.

[28] K. Yamauchi, “Airway remodeling in asthma and its influence on clinical pathophysiology,” Tohoku Journal of Experimental Medicine, vol. 209, no. 2, pp. 75–87, 2006.

[29] G. Riccioni, C. Di Ilio, and N. D’Orazio, “Pharmacological treatment of airway remodeling: inhaled corticosteroids or antileukotrienes?” Annals of Clinical and Laboratory Science, vol. 34, no. 2, pp. 138–142, 2004.

[30] A. M. Ghaemmaghami, L. Gough, H. F. Sewell, and F. Shaktiv, “The proteolytic activity of the major dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: allergen-induced Th2 bias determined at the dendritic cell level,” Clinical and Experimental Allergy, vol. 32, no. 10, pp. 1468–1475, 2002.

[31] E. Raz, H. Tighe, Y. Sato et al., “Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 10, pp. 5141–5145, 1996.

[32] B. D. Medoff, S. Y. Thomas, and A. D. Luster, “T cell trafficking in allergic asthma: the ins and outs,” Annual Review of Immunology, vol. 26, pp. 205–232, 2008.

[33] J. D. Cañete, S. E. Martínez, J. Farrés et al., “Differential Th1/Th2 cytokine patterns in chronic arthritis: Interferon γ is highly expressed in synovium of rheumatoid arthritis compared with...
seronegative spondyloarthropathies,” *Annals of the Rheumatic Diseases*, vol. 59, no. 4, pp. 263–268, 2000.

[34] G. Trinchieri, “Interleukin-12 and its role in the generation or TH1 cells,” *Immunology Today*, vol. 14, no. 7, pp. 335–338, 1993.

[35] M. Wills-Karp, J. Luyimbazi, X. Xu et al., “Interleukin-13: central mediator of allergic asthma,” *Science*, vol. 282, no. 5397, pp. 2258–2261, 1998.

[36] S. H. Gavett, D. J. O’Hearn, C. L. Karp et al., “Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice,” *American Journal of Physiology - Lung Cellular and Molecular Physiology*, vol. 272, no. 2, pp. L253–L261, 1997.

[37] D. C. Webb, A. N. J. McKenzie, A. M. L. Koskinen, M. Yang, J. Mattes, and P. S. Foster, “Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity,” *Journal of Immunology*, vol. 165, no. 1, pp. 108–113, 2000.

[38] R. H. Wilson, G. S. Whitehead, H. Nakano, M. E. Free, J. K. Koils, and D. N. Cook, “Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness,” *American Journal of Respiratory and Critical Care Medicine*, vol. 180, no. 8, pp. 720–730, 2009.

[39] M. Akdis, O. Palomares, W. van de Veen, M. van Splunter, and C. A. Akdis, “T_{H17} and T_{H22} cells: a confusion of antimicrobial response with tissue inflammation versus protection,” *Journal of Allergy and Clinical Immunology*, vol. 129, no. 6, pp. 1438–1449.

[40] A. Cruz, S. A. Khader, E. Torrado et al., “Cutting edge: IFN-\( \gamma \) regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection,” *Journal of Immunology*, vol. 177, no. 3, pp. 1416–1420, 2006.

[41] C. Song, L. Luo, Z. Lei et al., “IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma,” *Journal of Immunology*, vol. 181, no. 9, pp. 6117–6124, 2008.

[42] R. Halwani, S. Al-Muhsen, and Q. Hamid, “Airway remodeling in asthma,” *Current Opinion in Pharmacology*, vol. 10, no. 3, pp. 236–245, 2010.

[43] J. M. Fox, E. Letellier, C. J. Oliphant, and N. Signoret, “TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes,” *Blood*, vol. 117, no. 6, pp. 1851–1860, 2011.

[44] G. M. Walsh, “Novel cytokine-directed therapies for asthma,” *Discovery Medicine*, vol. 11, no. 59, pp. 283–291.